Pfizer Enterprises SARL
Records under this name other than patents Pfizer Enterprises SARL holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 9 of 9 · Back to Pfizer Enterprises SARL
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,794,370 | Method for Treating Cancer Using Camptothecin Derivatives and 5-Fluorouracil Formerly held Term ended Ended no later than May 1, 2020 · Low confidence | Term ended | Ended no later than May 1, 2020 | Low confidence |
| US 6,403,569 | Method for treating cancer using camptothecin derivatives and 5-fluorouracil Term ended Term ended Apr 28, 2020 · From the USPTO record | Term ended | Term ended Apr 28, 2020 | From the USPTO record |
| US 6,664,242 | Composition and Method Comprising CPT-11 and a Pyrimidine Derivative for the Treatment of Cancer Lapsed on the fee record Ended Dec 16, 2011 · High confidence | Lapsed on the fee record | Ended Dec 16, 2011 | High confidence |
| US 6,562,834 | Combination Comprising Camptothecin and a Stilbene Derivative for the Treatment of Cancer Lapsed on the fee record Ended May 13, 2011 · High confidence | Lapsed on the fee record | Ended May 13, 2011 | High confidence |
| US 6,548,488 | Composition Comprising Camptothecin or a Camptothecin Derivative and an Alkylating Agent for the Treatment of Cancer Lapsed on the fee record Ended Apr 15, 2011 · High confidence | Lapsed on the fee record | Ended Apr 15, 2011 | High confidence |
| US 6,503,889 | Composition Comprising Camptothecin and a Pyrimidine Derivative for the Treatment of Cancer Lapsed on the fee record Ended Jan 7, 2011 · High confidence | Lapsed on the fee record | Ended Jan 7, 2011 | High confidence |
| US 6,500,953 | Preparation of Camptothecin and Nothapodytine Derivatives Lapsed on the fee record Ended Dec 31, 2010 · High confidence | Lapsed on the fee record | Ended Dec 31, 2010 | High confidence |
| US 6,486,320 | Preparation of Camptothecin and of Its Derivatives Lapsed on the fee record Ended Nov 26, 2010 · High confidence | Lapsed on the fee record | Ended Nov 26, 2010 | High confidence |
| US 6,476,043 | Use of Camptothecin Derivatives, with Reduced Gastrointestinal Toxicity Lapsed on the fee record Ended Nov 5, 2010 · High confidence | Lapsed on the fee record | Ended Nov 5, 2010 | High confidence |